Improving kidney cancer treatment by enhancing immune response
Sensitization to RIPK1-dependent death as a strategy to enhance response of renal cell carcinoma (RCC) to immunotherapy
This study is looking at how to help your immune system better fight kidney cancer by understanding a protein that helps cancer cells survive, with the hope of improving current treatments for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10721156 on NIH RePORTER |
What this research studies
This research investigates how to make kidney cancer cells more susceptible to immune attacks by understanding the mechanisms that allow them to survive. It focuses on the role of a specific protein, RIPK1, in regulating cell death and survival in response to immune signals. By targeting these survival mechanisms, the goal is to enhance the effectiveness of existing immunotherapies, such as immune checkpoint inhibitors, which have shown limited success in kidney cancer. Patients may be involved in trials that assess new treatment combinations aimed at improving their response to immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with renal cell carcinoma who have not responded adequately to current immunotherapy options.
Not a fit: Patients with early-stage kidney cancer or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for kidney cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in enhancing immune responses in cancer treatment, suggesting that this approach could lead to significant advancements in therapy.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Ting, Adrian T — Mayo Clinic Rochester
- Study coordinator: Ting, Adrian T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.